Lundbeck
Charl van Zyl currently serves as President & Chief Executive Officer at Lundbeck, where focus is on transforming the global pharmaceutical company specializing in brain diseases for sustainable growth. Prior experience includes positions as Executive Vice President Neurology at UCB, where leadership resulted in a $3B Euro Neurology portfolio and an average YoY revenue growth of 9%. Charl van Zyl also held the role of Executive Vice President at BSN medical, successfully driving a global commercial strategy that doubled growth within two years. Earlier career highlights include senior roles at Bausch & Lomb, JADO Technologies, Novartis Pharma, and Eli Lilly and Company, demonstrating a strong foundation in marketing, sales, and operational excellence. Educational background includes studies at the University of Cape Town.
This person is not in any offices
Lundbeck
42 followers
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.